165
Participants
Start Date
February 3, 2021
Primary Completion Date
January 25, 2024
Study Completion Date
January 25, 2024
Rozanolixizumab
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Mg0007 50077, New York
Mg0007 50096, Philadelphia
Mg0007 50090, Winston-Salem
Mg0007 50122, Miami
Mg0007 50120, Miami
Mg0007 50073, Tampa
Mg0007 50114, Indianapolis
Mg0007 50113, Houston
Mg0007 50092, Orange
Mg0007 50099, San Francisco
Mg0007 50323, Honolulu
Mg0007 50075, Augusta
Mg0007 50121, Lexington
Mg0007 50071, Edmonton
Mg0007 50066, Montreal
Mg0007 50124, Montreal
Mg0007 50070, Québec
Mg0007 50069, Toronto
Mg0007 40125, Ostrava - Poruba
Mg0007 40124, Prague
Mg0007 40128, Aalborg
Mg0007 40127, Aarhus
Mg0007 40126, Copenhagen
Mg0007 40129, Bordeaux
Mg0007 40360, Limoges
Mg0007 40132, Nice
Mg0007 40133, Paris
Mg0007 40131, Strasbourg
Mg0007 20160, Tbilisi
Mg0007 20161, Tbilisi
Mg0007 20163, Tbilisi
Mg0007 20164, Tbilisi
Mg0007 20165, Tbilisi
Mg0007 40134, Essen
Mg0007 40140, Göttingen
Mg0007 40139, Jena
Mg0007 40078, Leipzig
Mg0007 40177, Münster
Mg0007 40283, Bologna
Mg0007 40144, Milan
Mg0007 40307, Napoli
Mg0007 40146, Pavia
Mg0007 40148, Roma
Mg0007 40150, Roma
Mg0007 20035, Bunkyō City
Mg0007 20068, Chiba
Mg0007 20078, Hanamaki-shi
Mg0007 20079, Hiroshima
Mg0007 20075, Kobe
Mg0007 20071, Nagasaki
Mg0007 20077, Sendai
Mg0007 20070, Shinjuku-ku
Mg0007 20076, Shinjuku-ku
Mg0007 20032, Suita
Mg0007 40155, Gdansk
Mg0007 40154, Lodz
Mg0007 40151, Lublin
Mg0007 40153, Poznan
Mg0007 20169, Novosibirsk
Mg0007 20001, Saint Petersburg
Mg0007 20028, Saint Petersburg
Mg0007 20055, Saint Petersburg
Mg0007 40467, Niš
Mg0007 40160, Barcelona
Mg0007 40157, L'Hospitalet de Llobregat
Mg0007 40350, Murcia
Mg0007 40308, San Sebastián de los Reyes
Mg0007 20081, Taipei
Mg0007 20086, Taipei
UCB Biopharma SRL
INDUSTRY